“Avigen shareholders may also receive other payments as part of the deal. If the company gets a milestone payment from Genzyme Corp. in the 20 months after the closing of the sale, Avigen stockowners will get a share of the proceeds. If Genzyme gives up on the rights to products it licensed from Avigen and then MediciNova is able to sell or license them, Avigen stockholders then can get 50 percent of the proceeds.”